Scoop has an Ethical Paywall
License needed for work use Register

News Video | Policy | GPs | Hospitals | Medical | Mental Health | Welfare | Search


PHARMAC funds two more heart drugs

PHARMAC is to subsidise two more drugs to help fight heart disease after reaching an innovative agreement with the drugs’ supplier, AstraZeneca.

PHARMAC is to fund a new, expensive blood pressure lowering drug called candesartan, which may be valuable for patients whose blood pressure is not adequately controlled on other drugs. The drug is significantly more expensive than the current options available.

As well, PHARMAC has agreed to subsidise a new low dose beta-blocker called metoprolol succinate. According to new evidence it may give another treatment option for some people with heart failure.

The funding of the drug has been made possible as part of a package where AstraZeneca has dropped the price of one of its older blood pressure treatments, felodipine, which belongs to a class of drugs known as DHP CCBs.

PHARMAC General Manager Wayne McNee says the AstraZeneca agreement is a good example of how a co-operative environment can help all parties, with patients in particular getting the benefit.

“By freeing up funding in one area, we are able to invest in new drugs which will give prescribers more tools in their arsenal to fight cardiovascular disease.”

He says the company will be working with PHARMAC to ensure that candesarten is used appropriately. Under a risk sharing arrangement, the company will have to pay PHARMAC back if the drug is over-used.

Candesarten will be fully subsidised from December 1. Low dose metoprolol will be available after it obtains approval from the Ministry of Health.


For further information contact PHARMAC General Manager Wayne McNee.
Phone: (025) 429-212.

Advertisement - scroll to continue reading

Are you getting our free newsletter?

Subscribe to Scoop’s 'The Catch Up' our free weekly newsletter sent to your inbox every Monday with stories from across our network.

© Scoop Media

Advertisement - scroll to continue reading
Culture Headlines | Health Headlines | Education Headlines

International Art Centre: Rare Goldie Landscape Expected To Fetch $150,000

When Evening Shadows Fall is one of four works by Goldie included in a sale of Important and Rare Art at the International Art Centre in Parnell on November 28. Goldie painted only a handful of landscapes, concentrating mainly on indigenous portraits, which earned him a global reputation as NZ’s finest painter of respected Māori elders (kaumātua). More

Mark Stocker: History Spurned - The Arrival Of Abel Tasman In New Zealand

On the face of it, Everhardus Koster's exceptional genre painting The Arrival of Abel Tasman in New Zealand should have immense appeal. It cannot find a buyer, however, not because of any aesthetic defects, but because of its subject matter and the fate of the Māori it depicts. More



  • Wellington
  • Christchurch
  • Auckland

Join Our Free Newsletter

Subscribe to Scoop’s 'The Catch Up' our free weekly newsletter sent to your inbox every Monday with stories from across our network.